Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL747250 | 1.00 | DAO (0.56) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL29486393 | 1.00 | DAO (0.56) | DAOAXLNUDT1AURKAPARP1 | |
| Trifluoroacetic Acid SCHEMBL29713497 | 0.86 | DAO (0.48) | DAORIPK1 | |
| SCHEMBL5794083 | 0.76 | DAO (0.47) | DAOAXLNUDT1RIPK1CCNB2 | |
| SCHEMBL4429036 | 0.74 | MAPT (0.50) | — | |
| SCHEMBL29498319 | 0.73 | DAO (0.53) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL126973 | 0.73 | DAO (0.53) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL491810 | 0.73 | PARP1 (0.42) | NUDT1AURKAPARP1 | |
| SCHEMBL5413200 | 0.73 | PARP1 (0.42) | NUDT1AURKAPARP1 | |
| Hydrochloric Acid SCHEMBL7181738 | 0.72 | DAO (0.51) | DAOAXLNUDT1AURKAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| EP-3978490-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, GNAQ | DAO 4577/4885AXL 2148/4885NUDT1 609/4885 |
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | KRAS, NRAS, GNAQ | DAO 4587/4885AXL 2727/4885NUDT1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.